GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longboard Pharmaceuticals Inc (NAS:LBPH) » Definitions » Institutional Ownership

Longboard Pharmaceuticals (Longboard Pharmaceuticals) Institutional Ownership : 42.54% (As of Jun. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Longboard Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Longboard Pharmaceuticals's institutional ownership is 42.54%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Longboard Pharmaceuticals's Insider Ownership is 0.98%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Longboard Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 73.96%.


Longboard Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Longboard Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longboard Pharmaceuticals Institutional Ownership Chart

Longboard Pharmaceuticals Historical Data

The historical data trend for Longboard Pharmaceuticals can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 42.52 40.40 38.63 38.19 36.21 37.25 40.61 42.80 42.58 42.54

Longboard Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Longboard Pharmaceuticals (Longboard Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4275 Executive Square, Suite 950, La Jolla, CA, USA, 92037
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
Executives
Randall Kaye officer: CMO 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Jane Tiller director C/O LONGBOARD PHARMACEUTICALS, INC., 4275 EXECUTIVE DRIVE, SUITE 950, LA JOLLA CA 92037
Brandi Roberts officer: Chief Financial Officer 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Phillip M Schneider director GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121
Vincent Aurentz director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Kevin Robert Lind director, officer: President and CEO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Paul J Sekhri director C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Casey Lynch director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Le Goff Corinne director 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Arena Pharmaceuticals Inc 10 percent owner 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Philip Perera officer: Chief Medical Officer C/O LONGBOARD PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121